International Keynote Speakers

Byong Cho, a pioneer in the exosome industry, has been the founder, CEO, and CTO of ExoCoBio Inc since 2017. He majored in molecular biology from 1991 to 1997 for a BS and MSc degree and achieved a Techno-MBA degree from KAIST, South Korea. With this unique combination, over the last two decades, he has been highly successful in technology commercialization in the venture capital industry as well as biotech management. He has generated significant returns on investment from early-stage biotech startups, including Medytox (Botulinum toxin aesthetics/pharmaceuticals), Viromed (Gene therapy), and others. The combined market capitalization of these companies reached approximately $5 billion. Moreover, he is the only person with hands-on experience in the Initial Public Offering (IPO) of two biotech startups in South Korea. In January 2017, leveraging his extensive experience in biotech, aesthetics, and investment, he established ExoCoBio to create an exosome-based regenerative therapeutics and aesthetics business. Byong Cho is the first author of the publication titled “Exosomes derived from human adipose tissue-derived mesenchymal stem cells alleviate atopic dermatitis”, published in Stem Cell Research & Therapy in 2018. This groundbreaking research demonstrated that stem cell-derived exosomes can be a viable drug candidate for inflammatory skin diseases, marking a global first. He holds more than 50 patents, in addition to over 10 publications, covering a variety of exosomes and their clinical applications. Byong Cho is a prolific lecturer with more than 50 lectures in the last three years at events worldwide, ranging from IMCAS World Congress, IMCAS Americas, AMWC Monaco, Dubai Derma, Saudi Derm, ISCT, Vegas Cosmetic Surgery & Aesthetic Dermatology, AIME Conference, FACE, ISEV, CCR, MEIDAM, IFATS, iCAST, AIRMESS, etc.